Associate Professor of Medicine, Beth Israel Deaconess Medical Center

Hematology

David Avigan works in the field of Hematology. He researched medicine at Yale University School of Medicine. Yale University School of Medicine is one of the top medical schools in the US. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine He over the years received 3 awards: "Regional Top Doctor", "Meaningful Use Stage 1 Certification" and "Super Doctor". David Avigan has written publications. He has 28 publications published with PubMed. The lastest publication is: 'MUC1-C drives MYC in multiple myeloma.' David Avigan accepts Medicare payments and is listed with Medicare.gov.

Publications

---

• MUC1-C drives MYC in multiple Myeloma.
• Role of Immune Therapies for Myeloma.
• Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic Cancers after allogeneic hematopoietic stem cell transplan...
• Dendritic cell Cancer vaccines: from the bench to the bedside.
• Targeting the MUC1-C oncoprotein is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated multiple myeloma Cell death.
• Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Selective Control of JC Virus Reactivation.
• Immunotherapy for multiple Myeloma.
• MUC1-C oncoprotein promotes FLT3 receptor activation in Acute myeloid leukemia cells.
• Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: ...
• MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells.
• Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients.
• The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation.
• Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of Chronic GVHD.
• Lenalidomide enhances anti-myeloma Cellular immunity.
• Phase II Trial of Parathyroid Hormone following Double Umbilical Cord Blood Transplantation.
• Dendritic/tumor fusion cells as Cancer vaccines.
• Interleukin-2 and regulatory T cells in Graft-versus-host disease.
• Incidence of contrast-induced nephropathy in patients with multiple Myeloma undergoing contrast-enhanced CT.
• Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple Myeloma.
• Defibrotide for the treatment of severe hepatic veno-occlusive Disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding ...
• Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple Myeloma.
• Single-agent bortezomib in previously untreated multiple Myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neu...
• Phase I/II study of vaccination with electrofused allogeneic dendritic Cells/autologous tumor-derived Cells in patients with stage IV renal Cell carcinoma.
• Innovations and challenges in renal Cancer: consensus statement from the first international conference.
• Detection of Staphylococcus aureus in peripheral blood stem Cell cultures after sterilization of standard blood cultures.
• Update on Cancer vaccines.
• Clinical trials of dendritic cell-based Cancer vaccines in hematologic malignancies.

Schools

---

• Yale University School Of Medicine

• Columbia Pamps

• Sloan Kettering Meml Hospital

Procedures Preformed

---

• Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
• HPC Transplantation (Stem Cell Transplant)
• Plasmapheresis
• Thoracentesis

Conditions Treated

---

• Acute Leukemia
• Anal and Rectal Cancer
• Anemia
• Antiphospholipid Syndrome (APS)
• View All

Doctors Specialties

---

• Hematology
• Medical Oncology
• Oncology

Accepted Insurances

---

Awards

---

• Regional Top Doctor
• Meaningful Use Stage 1 Certification
• Super Doctor

Education

---

• Memorial Sloan-Kettering Cancer Center
• New York Presbyterian Hospital - Columbia Campus
• Yale University School of Medicine

Hospital

---

• Beth Israel Deaconess Medical Center

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1952349243
Last Name Of The Provider	AVIGAN
First Name Of The Provider	DAVID
View All

Similar Doctors

---

	Dr. Matthew L. Freedman, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Xiuning Le, MD
	Dr. Cindy Varga, MD
	Dr. Curtis R. Chong, MD
	Dr. Frank C. Kuo, MD This Doctor is OpenDoctor Recommended.
	Dr. Ruth M. Ruprecht, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Bradley W. Blaser, MD This Doctor is OpenDoctor Recommended.
	Dr. Deepa Rangachari, MD This Doctor is OpenDoctor Recommended.
	Dr. Jerome E. Groopman, MD This Doctor is OpenDoctor Recommended.
	Dr. John Koreth, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Edward J. Benz Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Julie A. Krutiak, MD This Doctor is OpenDoctor Recommended.
	Dr. Geoffrey K. Sherwood, MD This Doctor is OpenDoctor Recommended.
	Dr. Sarah M. Scott, MD
	Dr. Murray M. Bern, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Rebecca S. Karp, MD This Doctor is OpenDoctor Recommended.
	Dr. Catherine A. Shu, MD
	Dr. Andreas K. Klein, MD This Doctor is OpenDoctor Recommended.
	Dr. Gunjan L. Shah, MD
	Dr. John M. Sloan, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog